Chimerix ((CMRX)) announced an update on their ongoing clinical study.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Chimerix is conducting a Phase I study titled ‘A First-in-human Phase I Single-agent Dose-escalation, Food Effect and Dose Expansion Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms.’ The study aims to evaluate the safety and tolerability of ONC206, a drug designed to treat recurrent CNS tumors, by determining the maximum-tolerated dose and identifying any dose-limiting toxicities.
ONC206, the drug under investigation, is an experimental anti-cancer small molecule targeting G protein-coupled receptors. It belongs to the imipridone class and is being tested for its effectiveness in treating central nervous system neoplasms.
This interventional study follows a single-group assignment model without masking, focusing on treatment as its primary purpose. The study is open-label, meaning both researchers and participants know which treatment is being administered.
The study began on October 26, 2020, and is currently recruiting participants. The last update was submitted on July 30, 2025. These dates are crucial for tracking the study’s progress and ensuring timely updates for stakeholders.
The ongoing study could influence Chimerix’s stock performance, as positive results may boost investor confidence and market value. The competitive landscape includes other companies researching CNS treatments, which could affect market dynamics.
The study is ongoing, and further details are available on the ClinicalTrials portal.